SAREPTA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
SAREPTA THERAPEUTICS, INC. (SRPT) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 0.70% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2025-02-28
- SAREPTA THERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 0.70%.
- SAREPTA THERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -3.80%.
- SAREPTA THERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -1.60%, a 1700.00% decline from fiscal 2021.
- SAREPTA THERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2021 was 0.10%, a 75.00% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | 0.70% 10-K · filed 2025-02-28 | |
| 2023-12-31 | -3.80% 10-K · filed 2025-02-28 | |
| 2022-12-31 | -1.60% 10-K · filed 2025-02-28 | 1.60% 10-K · filed 2023-02-28 |
| 2021-12-31 | 0.10% 10-K · filed 2024-02-28 | |
| 2020-12-31 | 0.40% 10-K · filed 2023-02-28 | 0.20% 10-K · filed 2021-03-01 |
| 2019-12-31 | 0.10% 10-K · filed 2022-03-01 | |
| 2018-12-31 | 3.40% 10-K · filed 2021-03-01 | |
| 2017-12-31 | 0.40% 10-K · filed 2020-02-26 | |
| 2012-12-31 | 0.00% 10-K · filed 2013-03-15 | |
| 2011-12-31 | -31.20% 10-K · filed 2014-03-03 | |
| 2010-12-31 | -8.30% 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |